Avacta Highlights AVA6103 Activity In Enhertu-Resistant Tumors, Advances Phase 1 Study

Avacta Therapeutics reported preclinical data showing antitumor activity for AVA6103, an investigational FAP-activated exatecan peptide-drug conjugate, in HER2-positive, FAP-positive gastric tumors that had progressed after treatment with a drug named only partially as “Enhe” in the provided text. The findings are early-stage and preclinical; the article excerpt provides no numerical efficacy results or market reaction.